Actemra (tocilizumab subcutaneous injection - Genentech/Roche) — Cigna
Polyarticular Juvenile Idiopathic Arthritis
Initial criteria
- Patient age > 2 years
- Patient has tried ONE other systemic therapy for this condition (examples include methotrexate, sulfasalazine, leflunomide, or a nonsteroidal anti-inflammatory drug [NSAID]) OR a previous trial of one biologic other than the requested drug
- Criteria continue beyond this excerpt but initial elements listed are explicit in this section
Approval duration
6 months (initial)